| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698028 | Clinical Oncology | 2017 | 7 Pages |
Abstract
There is no clear consensus or evidence on the defined role of SABR in gynaecological tumours. Local control and toxicity associated with SABR seems reasonable for most clinical indications found by this review with a short median follow-up. When used for salvage of non-nodal pelvic recurrences, SABR may be associated with high rates of grade 3-4 late gastrointestinal toxicity.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
L.C. Mendez, E. Leung, P. Cheung, L. Barbera,